The first EGFR tyrosine kinase inhibitor (TKI) was approved for clinical use in 2003 and was mostly used in patients with non-small-cell lung cancer (NSCLC) carrying EGFR-activating mutations and in patients with breast and pancreatic cancers. Here, EGFR is linked to pancreatic neoplasm.